Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal goblet cell carcinomas with peritoneal carcinomatosis: results from a single specialized center

  • Hsin-Hsien Yu, Yutaka Yonemura, Mao-Chih Hsieh, Akiyoshi Mizumoto, Satoshi Wakama, Chang-Yun Lu
  • Cancer Management and Research, October 2017, Dove Medical Press
  • DOI: 10.2147/cmar.s147227

Cytoreductive surgery and HIPEC for appendiceal goblet cell carcinomas with PC.

What is it about?

The aim of the present article is to describe our experience in the management of GCCs with peritoneal carcinomatosis (PC) through cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) and to determine the impact of multiple clinical characteristics on the prognosis.

Why is it important?

The estimated median survival after the diagnosis of GCC with PC and after definitive CRS–HIPEC was 28 and 17 months, respectively. The 1-, 2-, 3-, 4-year survival rates were 86%, 69%, 57%, and 24%, respectively. Log-rank test revealed that the significant independent risk factors for more favorable outcomes were age >50 years, peritoneal cancer index (PCI) <27, postoperative PCI <20, administration of HIPEC, and adjuvant chemotherapy.

Perspectives

Hsin-Hsien Yu
Wan Fang Hospital, Taipei Medical University, Taiwan

Previous studies reported a median survival of 7 months (range: 5–24 months) in patients with GCC and PC, who underwent debulking surgery alone. We recommend CRS and HIPEC, followed by adjuvant systemic chemotherapy, as a promising strategy to improve survival, especially in selected patients with low PCI and possibility to achieve complete cytoreduction.

open access logoRead Publication

http://dx.doi.org/10.2147/cmar.s147227

The following have contributed to this page: Hsin-Hsien Yu, Mao-Chih Hsieh, and Changyun Lu